Is Anticoagulant Monotherapy Sufficient for Patients with Atrial Fibrillation and Stable Coronary Disease?

In a multicenter randomized trial, edoxaban monotherapy reduced nonfatal major and clinically relevant nonmajor bleeding without excess risk for ischemic events.

In most patients with atrial fibrillation (AF) and a recent percutaneous coronary intervention or acute coronary syndrome, dual therapy with an anticoagulant plus a single antiplatelet drug reduces the risk for bleeding events without a major increase in ischemic events (NEJM JW Cardiol Mar 17 2019 and N Engl J Med 2019; 380:1509; and NEJM JW Cardiol Sep 3 2019 and Lancet 2019; 394:1335). Nevertheless, the optimal regimen for patients with AF and stable coronary artery disease (CAD) remains unclear. In the industry-funded, multicenter, open-label, randomized EPIC-CAD trial from South Korea, researchers compared edoxaban monotherapy with anticoagulation plus clinician-selected antiplatelet monotherapy in 1040 patients with AF and stable CAD …

Reviewing Author

Behnood Bikdeli, MD, MS

Disclosures

Grant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians

Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology

Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis

Behnood Bikdeli, MD, MS

Disclosures

Grant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians

Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology

Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis

Is Anticoagulant Monotherapy Sufficient for Patients with Atrial Fibrillation and Stable Coronary Disease?

Topics

Reviewing Author